4.7 Article

CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement

期刊

BMJ-BRITISH MEDICAL JOURNAL
卷 350, 期 -, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmj.h1738

关键词

-

资金

  1. Alberta Innovates - Health Solutions (AHIS)
  2. Afexa Life Sciences
  3. Hecht Foundation
  4. HEEL
  5. Pfizer USA
  6. Schwabe Pharma
  7. Canadian Institutes for Health Research [86766]
  8. AHIS as a health scholar
  9. MRC [MR/J004871/1] Funding Source: UKRI
  10. Cancer Research UK [16895] Funding Source: researchfish
  11. Medical Research Council [MR/J004871/1] Funding Source: researchfish

向作者/读者索取更多资源

N-of-1 trials provide a mechanism for making evidence based treatment decisions for an individual patient. They use key methodological elements of group clinical trials to evaluate treatment effectiveness in a single patient, for situations that cannot always accommodate large scale trials: rare diseases, comorbid conditions, or in patients using concurrent therapies. Improvement in the reporting and clarity of methods and findings in N-of-1 trials is essential for reader to gauge the validity of trials and to replicate successful findings. A CONSORT extension for N-of-1 trials (CENT 2015) provides guidance on the reporting of individual and series of N-of-1 trials. CENT provides additional guidance for 14 of the 25 items of the CONSORT 2010 checklist and recommends a diagram for depicting an individual N-of-1 trial and modifies the CONSORT flow diagram to address the flow of a series of N-of-1 trials. The rationale, development process, and CENT 2015 checklist and diagrams are reported in this document.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据